Hepatitis C virus: Here comes all-oral treatment

  • Dugum M
  • O'Shea R
  • 37

    Readers

    Mendeley users who have this article in their library.
  • 15

    Citations

    Citations of this article.

Abstract

Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new direct-acting antivirals-sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)-opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free